Zur Personenübersicht
  • Professor

Prof. Dr. Carsten Boltze

Professor für Medizinische Grundlagen, Studiengang Medizinpädagogik, B.A.
E-Mail:
Telefon: +49 (0) 365 773407 -10

Über mich
Über mich

2016 - Aktuell
Professor im Studiengang Medizinpädagogik an der SRH Hochschule für Gesundheit am Campus Gera.

2013
Privatdozent an die Friederich-Alexander-Universität Erlangen-Nürnberg umhabilitiert.

2007
Johannes-Zange-Preis

2006
Wechsel als Chefarzt an das SRH Wald-Klinikum Gera.

2005
Ernennung zum Oberarzt am Universitätsklinikum Rostock.

2005
Habilitation mit Forschungsergebnissen zur Tumorentstehung in der Schilddrüse.

2004
Der erste Juniorprofessor für Pathologie in Deutschland.

2004
Johannes-Zange-Preis

2003
Johannes-Zange-Preis

2002
Merck European Thyroid Von Basedow Research Prize.

2000
Promotion mit „summa cum laude“

1998
Approbation als Arzt. Die Weiterbildung zum Facharzt für Pathologie absolvierte er an den Universitätskliniken in Magdeburg und Rostock.

1970
Prof. Dr. habil. Carsten Boltze in Sondershausen/Thüringen geboren

Auszug
An diesen Publikationen habe ich mitgewirkt

2017
Wolfram F, Dietrich G, Boltze C, Jenderka KV, Lesser TG (2017) Effects of HIFU induced cavitation on flooded lung parenchyma. J Ther Ultrasound, 5:21-28 IF: 1.455

2017
Weyerer V, Schneckenpointner R, Filbeck T, Burger M, Hofstaedter F, Wild PJ, Fine SW, Humphrey PA, Dehner LP, Amin MB, Rüschoff J, Boltze C, Tannapfel A, Zwarthoff E, LopezBeltran A, Montironi R, Langner C, Stoehr R, Hartmann A, Giedl J (2017) Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years. J Cancer, 8:323-331 IF: 2.916

2016
Lesser TG, Boltze C, Schubert H, Wolfram F (2016) Flooded Lung Generates a Suitable Acoustic Pathway for Transthoracic Application of High Intensity Focused Ultrasound in Liver. Int J Med Sci, 13:741-748 IF: 2.399

2016
Hunstig F, Schulz S, Nieten I, Froster U, Boltze C, Schliemann S, Hochhaus A, La Rosée P (2016) A case of Brooke-Spiegler syndrome with a novel mutation in the CYLD gene in a patient with aggressive non-Hodgkin's lymphoma. J Cancer Res Clin Oncol, 142:845-848 IF: 3.081

2016
Foerster G, Arnold D, Bischoff S, Boltze C, Scholle HC, Schubert H, Mueller AH (2016) Preclinical evaluation of a minimally invasive laryngeal pacemaker system in mini-pig. Eur Arch Otorhinolaryngol, 273:151-158 IF: 1.545

2015
Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi, M,Wolff HA, Lang-Welzenbach M, Raab HR, Wittekind C, Ströbel P, Staib L, Wilhelm M, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, Liersch T; Boltze C et al. for German Rectal Cancer Study Group (2015) Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol, 16:979-989 IF: 24.725

2015
Haller F, Bieg M, Moskalev EA, Barthelmeß S, Geddert H, Boltze C, Diessl N, Braumandl K, Brors B, Iro H, Hartmann A, Wiemann S, Agaimy A (2015) Recurrent Mutations within the AminoTerminal Region of β-Catenin are probable Key Molecular Driver Events in Sinonasal Hemangiopericytoma. Am J Pathol, 185:563-571 IF: 6.750

2014
Agaimy A, Barthelmeß S, Geddert H, Boltze C, Moskalev EA, Koch M, Wiemann S,Hartmann A, Haller F (2014) Phenotypical and molecular distinctness of sinonasal haemangiopericytoma compared to solitary fibrous tumour of the sinonasal tract. Histopathology, 65:667-673 IF: 4.131

2014
Moskalev EA, Frohnauer J, Merkelbach-Bruse S, Schildhaus H, Dimmler A, Schubert T,BoltzeC, König H, Fuchs F, Sirbu H, Rieker RJ, Agaimy A, Hartmann A, Haller F (2014) Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing.Lung Cancer, 84:215-221 IF: 3.373

2014
Barthelmeß S, Geddert H, Boltze C, Moskalev EA, Bieg M, Sirbu H, Brors B, Wiemann S, Hartmann A, Agaimy A, Haller F (2014) Solitary fibrous tumors/hemangiopericytomas with different variants of the NAB2-STAT6 gene fusion are characterized by specific histomorphology and distinct clinicopathological features.Am J Pathol, 184:1209-1218 IF: 6.750

2014
Wolfram F, Boltze C, Schubert H, Bischoff S, Lesser TG (2014) Effect of lung flooding and highintensity focused ultrasound on lung tumours: an experimental study in an ex vivo human cancer model and simulated in vivo tumours in pigs. Eur J Med Res,19:1-9 IF: 1.400

2013
Moskalev EA, Stöhr R, Rieker R, Hebele S, Fuchs F, Sirbu H, Mastitsky SE, Boltze C, König H, Agaimy A, Hartmann A, Haller F (2013) Increased detection rates of EGFR and KRAS mutations in NSCLC specimens with low tumour cell content by 454 deep sequencing. Virchows Arch, 462:409-419 IF: 2.227

2013
Lesser TG, Wolfram F, Boltze C (2013) Sealing of pulmonary arteries with LigaSure: In vivo and ex vivo examinations.J Thorac Cardiovasc Surg, 145:1525-1528 IF: 3.406

2012
Lesser K, Boltze C, Böttcher J, Lesser TG (2012) Cystic medionecrosis of the carotid bifurcation as an uncommon cause of stroke. Neurologist, 18:395-397 IF: 1.662

2012
Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, LangWelzenbach M, Raab HR, Sülberg H, Wittekind C, Potapov S, Staib L, Hess C, Weigang-Köhler K, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, Boltze C et al. for German Rectal Cancer Study Group (2012) Preoperative chemoradiotherapy and Seite 7 von 8 postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol, 13:679-687 IF: 24.725

2011
Lesser TG, Ritter F, Schlosser H, Boltze C, Hackenbroich C (2011) Effects of radiofrequency ablation on normal lung tissue in a swine model. Acad Radiol, 18:1318-1323 IF: 2.195

2009
Schmuecking M, Boltze C, Geyer H, Salz H, Schilling B, Wendt TG, Kloetzer KH, Marx C (2009) Dynamic MRI and CAD vs. choline MRS: where is the detection level for a lesion characterisation in prostate cancer? Int J Radiat Biol, 85:814-824 IF: 2.690

2009
Boltze C, Riecke A, Ruf CG, Port M, Nizze H, Kügler C, Miethke C, Wiest N, Abend M (2009) Sporadic and radiation-associated papillary thyroid cancers can be distinguished using routine immunohistochemistry. Oncol Rep, 22:459-467 IF: 1.525

2009
Naka T, Boltze C, Samii A, Samii M, Herold C, Ostertag H, Iwamoto Y, Oda Y, Tsuneyoshi M, Kuester D, Roessner A (2009) Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma. Histopathology, 54:607-613 IF: 4.131

2009
Punke C, Zehlicke T, Boltze C, Pau HW (2009) Investigation of a new highly porous hydroxyapatite matrix for obliterating open mastoid cavities - application in guinea pigs bulla.Laryngo Rhino Otol, 88:241-246 IF: 0.507

2008
Naka T, Kuester D, Boltze C, Schulz TO, Samii A, Herold C, Ostertag H, Roessner A (2008) Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma. Hum Pathol, 39:217-223 IF: 3.685

2008
Zehlicke T, Punke C, Boltze C, Pau HW (2008) Transient facial palsy in two cases of benign, very rare middle ear tumors (carcinoid tumor and myxoma). Neurologist, 14:52-55 IF: 1.662

2008
Förster G, Boltze C, Seidel J, Pawlita M, Müller A (2008) Juvenile laryngeal papillomatosis - immunisation with the polyvalent vaccine gardasil.Laryngo Rhino Otol, 87:796-799 IF: 0.507

2008
Punke C, Zehlicke T, Boltze C, Pau HW (2008) Experimental studies on a new highly porous hydroxyapatite matrix for obliterating open mastoid cavities. Otol Neurotol, 29:807-811IF: 1.219

2008
Naka T, Kuester D, Boltze C, Scheil-Bertram S, Samii A, Herold C, Ostertag H, Krueger S, Roessner A (2008) Expression of hepatocyte growth factor and c-MET in skull base chordoma. Cancer, 112:104-110 IF: 4.434

2008
Zehlicke T, Punke C, Haase K, Boltze C, Pau HW (2008) Myxoma of the middle ear-a rare cause of facial palsy. HNO, 56:165-168 IF: 0.653

2007
Port M, Boltze C, Wang Y, Röper B, Meineke V, Abend M (2007) A radiation-induced gene signature distinguishes post-Chernobyl from sporadic papillary thyroid cancers.Radiat Res, 168:639-649 IF: 3.043

2006
Just T, Stave J, Boltze C, Wree A, Kramp B, Guthoff RF, Pau HW (2006) Laser scanning microscopy of the human larynx mucosa: a preliminary, ex vivo study. Laryngoscope, 116:1136- 1141IF: 1.576

2006
Aust G, Wandel E, Boltze C, Sittig, D, Steinert M, Schütz A, Horn LC, Wobus M (2006) Diversity of CD97 in smooth muscle cells (SMCs). Cell Tissue Res, 324:139-147 IF: 2.750

2006
Schneider-Stock R, Kuester D, Ullrich O, Mittag F, Habold C, Boltze C, Peters B, Krueger S, Hintze C, Meyer F, Hartig R, Roessner A (2006) Close localization of DAP-kinase positive tumorassociated macrophages and apoptotic colorectal cancer cells. J Pathol, 209:95-105 IF: 5.333

2006
Röpke M, Boltze C, Meyer B, Neumann HW, Roessner A, Schneider-Stock R (2006) Rb-loss is associated with high malignancy in chondrosarcoma. Oncol Rep, 15:89-95 IF: 1.525

2006
Hribaschek A, Kuhn R, Pross M, Meyer F, Fahlke J, Ridwelski K, Boltze C, Lippert H (2006) Comparison of intraperitoneal versus intravenous CPT-11 given intra- and postoperatively for peritoneal carcinomatosis in a rat model. Surg Today, 36:57-62 IF: 0.553

2005
Naka T, Boltze C, Kuester D, Samii A, Herold C, Ostertag H, Iwamoto Y, Oda Y, Tsuneyoshi M, Roessner A (2005) Intralesional fibrous septum in chordoma: A clinicopathologic and immunohisto-chemical study of 122 lesions. Am J Clin Pathol, 124:288-294 IF: 2.853

2005
Boltze C (2005) Loss of maspin is a helpful prognosticator in colorectal cancer: A tissue microarray analysis. Pathol Res Pract, 200:783-790 IF: 1.073

2005
Naka T, Boltze C, Kuester D, Schulz TO, Schneider-Stock R, Kellner A, Samii A,Herold C, Ostertag H, Roessner A (2005) Alterations of G1-S checkpoint in chordoma: Prognostic impact of p53 overexpression. Cancer, 104:1255-1263 IF: 4.434

2005
Dworakowska D, Jassem E, Jassem J, Boltze C, Wiedorn KH, Dworakowski R, Skokowski J, Jaskiewicz K, Czestochowska E (2005) Prognostic value of cyclin D1 overexpression in correlation with pRb and p53 status in non-small cell lung cancer (NSCLC).J Cancer Res Clin Oncol, 131:479-485 IF: 2.409

2005
Schneider-Stock R, Diab-Asseff M, Rohrbeck A, Foltzer-Jourdainne C, Boltze C,Hartig R, Schönfeld P, Roessner A, Gali-Muhtasib H (2005) 5 AZA-cytidine is a potent inhibitor of DNA methyltransferase 3a and induces apoptosis in HCT-116 colon cancer cells via Gadd45- and p53- dependent mechanisms. J Pharmacol Exp Ther, 312:525-536 IF: 4.335

2005
Dworakowska D, Jassem E, Jassem J, Boltze C, Wiedorn KH, Dworakowski R, Skokowski J, Jaskiewicz K, Czestochowska E (2005) Absence of prognostic significance of p21(WAF1/CIP1) protein expression in non-small cell lung cancer. Acta Oncol, 44: 75-79 IF: 2.084

2005
Mawrin A, Kirches E, Schneider-Stock R, Boltze C, Vorwerk CK, Deimling A, Stoltenburg-Didinge G, Bornemann A, Romeike B, Sellhaus B, Dietzmann K (2005) Alterations of cell cycle regulators in gliomatosis cerebri. J Neurooncol, 72:115-122 IF: 1.968

2004
Boltze C. Animal models of thyroid carcinogenesis. In: Farid NR (Ed.): Molecular basis of thyroid cancer. Kluwer Academic Publishers, Norwell, MA, 2004, pp 272-293

2004
Schneider-Stock R, Mawrin C, Motsch C, Boltze C, Peters B, Hartig R, Buhtz P, Giers A, Rohrbeck A, Freigang B, Roessner A (2004) Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. Am J Pathol, 164:1233-1241 IF: 6.750

2004
Boltze C (2004) Animal models of thyroid carcinogenesis. Cancer Treat Res, 122:273-293 IF: 3.515

2004
Motsch C, Giers A, Boltze C, Evert M, Freigang B, Roessner A, Schneider-Stock R (2004) Biallelic inactivation of the p16 gene in three metachronous carcinoma of the oropharynx. Laryngo Rhino Otol, 83:55-60 IF: 0.507

2003
Mawrin C, Diete S, Treuheit T, Kropf S, Vorwerk CK, Boltze C, Kirches E, Firsching R, Dietzmann K (2003) Prognostic relevance of MAPK expression in glioblastoma multiforme. Int J Oncol, 23:641-648 IF: 3.056

2003
Boltze C, Schneider-Stock R, Quednow C, Gerlach R, Mawrin C, Hinze R, Roessner A, Hoang-Vu C (2003) Proteome analysis identified Maspin as a special feature of papillary thyroid carcinoma. Int J Oncol, 23:1323-1328 IF: 3.056

2003
Boltze C, Mundschenk J, Unger N, Schneider-Stock R, Peters B, Mawrin C, Hoang-Vu C, Roessner A, Lehnert H (2003) Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma. J Clin Endocrinol Metab, 88:4280-4286 IF: 6.020

2003
Boltze C, Schneider-Stock R, Roessner A, Quednow C, Hoang-Vu C (2003) Function of HSP90 and p23 in the telomerase complex of thyroid tumors. Pathol Res Pract, 199:573-579 IF: 1.073

2003
Schneider-Stock R, Boltze C, Peters B, Höpfner T, Meyer F, Lippert H, Roessner A (2003) Differences in loss of p16INK4A protein expression by promoter methylation between left- and right-sided primary colorectal carcinomas. Int J Oncol, 23:1009-1013 IF: 3.056

2003
Boltze C, Schneider-Stock R, Quednow C, Hinze R, Mawrin C, Hribaschek A, Roessner A, HoangVu C (2003) Silencing of the Maspin gene by promoter hypermethylation in thyroid cancer.Int J Mol Med, 11:479-484 IF: 3.190

2003
Boltze C, Schneider-Stock R, Meyer F, Peters B, Quednow C, Hoang-Vu C, Roessner A (2003) Maspin in thyroid cancer: its relationship with p53 and clinical outcome. Oncol Rep, 10:1783- 1788 IF: 1.525

2003
Boltze C, Zack S, Quednow C, Bettke S, Roessner A, Schneider-Stock R (2003) Hypermethylation of the CDKN2 / p16INK4A promotor in thyroid carcinogenesis.Pathol Res Pract, 199:399-404 IF: 1.073

2003
Boltze C, Hribaschek A, Lippert H, Roessner A (2003) Intermuscular chondrolipoma of the thigh: the diagnostic way of a rare entity. Pathol Res Pract, 199:503-507 IF: 1.073

2002
Hribaschek A, Pross M, Kuhn R, Krüger S, Ridwelski K, Halangk W, Boltze C, Lippert H (2002) Prevention and treatment of peritoneal carcinomatosis in experimental investigations with CPT11 and oxaliplatin. Anti-Cancer Drugs, 13:605-614 IF: 2.052

2002
Schneider-Stock R, Boltze C, Jäger V, Stumm M, Seiler C, Rys J, Schütze K, Roessner A (2002) Significance of loss of heterozygosity of the RB1 gene during tumour progression in welldifferentiated liposarcomas. J Pathol, 197:654-660 IF: 5.333

2002
Aust G, Steinert M, Schütz A, Boltze C, Wahlbuhl M, Hamman J, Wobus M (2002) CD97, but not its closely related EGF-TM7 family member EMR2 is expressed on gastric, pancreatic and esophageal carcinomas. Am J Clin Pathol, 118:699-707 IF: 2.853

2002
Hoang-Vu C, Boltze C, Gimm O, Poremba C, Dockhorn-Dworniczak B, Köhrle J, Rath FW, Dralle H (2002) Expression of telomerase genes in thyroid carcinoma. Int J Oncol, 21:265-272 IF: 3.056

2002
Boltze C, Roessner A, Landt O, Szibor R, Peters B, Schneider-Stock R (2002) Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma.Int J Oncol, 21:1151-1154 IF: 3.056

2002
OndruschkaC, Buhtz P, Motsch C, Freigang B, Schneider-Stock, Roessner A, Boltze C (2002)Prognostic value of MMP-2, -9 and TIMP-1, -2 immunoreactive protein at the invasive front in advanced head and neck squamous cell carcinomas. Pathol Res Pract, 198:509-515 IF: 1.073

2002
Schneider-Stock R, Boltze C, Roessner A. Telomerase activity in mesenchymal tumors. In: Krupp G, Pawaresch R (Eds.): Telomeres and Telomerases: Cancer and Biology. LandesBioscience / Eurekah.com, Georgetown,TX, 2002, pp 41-46

2002
Mawrin C, Kirches E, Boltze C, Dietzmann K, Roessner A, Schneider-Stock R (2002) Immunohistochemical and molecular analysis of p53, Rb and PTEN in malignant peripheral nerve sheath tumors. Virchows Arch, 440:610-615 IF: 2.227

2002
Boltze C, Schneider-Stock R, Aust G, Mawrin C, Dralle H, Roessner A, Hoang-Vu C (2002) CD97, CD95 and Fas-L clearly discriminate between chronic pancreatitis and pancreatic ductal adenocarcinoma in perioperative evaluation of cryocut sections. Pathol Int, 52:83-88 IF: 1.073

2002
Mawrin C, Lins H, Koenig B, Heinrichs T, Murayama S, Kirches E, Boltze C, Dietzmann K (2002) Spatial and temporal disease progression of adult-onset subacute sclerosing panencephalitis.Neurology, 58:1568-1571IF: 5.973

2002
Boltze C, Brabant G, Dralle H, Gerlach R, Roessner A, Hoang-Vu C (2002) Radiation-induced thyroid carcinogenesis as function of time and dietary iodine supply - An in-vivo model of tumorigenesis in the rat.Endocrinology, 143:2584-2592 IF: 5.313

2001
Hribaschek A, Kuhn R, Pross M, Lippert H, Halangk W, Boltze C, Ridwelski K (2001) Prophylaxis of peritoneal carcinomatosis in experimantal investigations. Int J Colorectal Dis, 16:340-345 IF: 1.902

2001
Aust G, Steinert M, Boltze C, Kiessling S, Simchen C (2001) GRO- in normal and pathological thyroid tissues and its regulation in thyroid-derived cells. J Endocrinol, 170:513-520 IF: 3.319

2001
Boltze C, Schneider-Stock R, Jäger V, Roessner A (2001)Distinction between lipoma and liposarcoma by mdm2 alterations: a case report of simultaneously occurring tumors and review of the literature. Pathol Res Pract, 197:563-568 IF: 0.850

2000
Hinze R, Boltze C, Meye A, Holzhausen HJ, Dralle H, Rath FW (2000) Expression of the von Hippel-Lindau tumor suppressor gene in nonneoplastic and neoplastic lesions of the thyroid. Endocr Pathol, 11:145-155 IF: 1.724

1999
Hoang-Vu C, Boltze C, Sekulla C, Dralle H, Gerlach R, Dunst J, Holzhausen HJ, Brabant G. Functional and histomorphological changes of thyrocytes under different iodine intake and external ionizing radiation in rats. In: Thomas G, Karaoglou A, Williams ED (Eds.): Radiation and thyroid cancer. World Scientific, Singapur, New Jersey, London, Hongkong, 1999, pp 209-212